HOME >> MEDICINE >> NEWS
New protease inhibitor held HIV at undetectable levels for four years

A study from The Feinberg School of Medicine has shown that the protease inhibitor lopinavir/ritonavir (Kaletra) suppressed HIV to undetectable levels and was well tolerated through four years of treatment in patients who had not previously received antiretroviral therapy.

To date in the Kaletra study, none of the patients has developed resistance to Kaletra or other protease inhibitors. Kaletra is thus far the only protease inhibitor for which resistance has not been observed in patients receiving it as an initial therapy.

Robert L. Murphy, M.D., professor of medicine at the Feinberg School and director of HIV/AIDS clinical research at Northwestern University, presented results of the study today at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy.

"Maintaining antiviral suppression to undetectable levels over the long term is crucial to patients' success," Murphy said.

"Drugs such as Kaletra, which have demonstrated high rates of viral suppression over several years, remain important options for initial therapy. Viral suppression helps prolong the time to development of resistance, which is an important cause of treatment failure," Murphy said.

In this ongoing phase II study, 100 patients who had not previously received antiretroviral therapy were given one of three doses of Kaletra in addition to the nucleoside analogues stavudine and lamivudine.

After 48 weeks, therapy for all patients was converted to the same dose of Kaletra with stavudine and lamivudine. Of the original group of patients, 72 remained in the study through four years; seven of the 28 patients who discontinued therapy did so because of adverse events attributed to Kaletra. All 72 patients maintained an undetectable HIV viral load of less than 400 copies per milliliter, and their CD4 counts increased consistently from the beginning of the study over the four-year period (mean increase of 416 cells per cubic millimeter).

Ka
'"/>

Contact: Elizabeth Crown
e-crown@northwestern.edu
312-503-8928
Northwestern University
27-Sep-2002


Page: 1 2

Related medicine news :

1. HIV patients may be at risk of heart problems when taking protease inhibitor drugs
2. HIV-1 protease inhibitors: Effective against malaria?
3. FDA approves new HIV protease inhibitor, Lexiva (TM)
4. Pharmacokinetic data presented at ICAAC on investigational HIV protease inhibitor 433908 (908)
5. Molecules inhibit HIV protease, could lead to new line of attack against AIDS
6. Study compares efficacy and adherence to triple nucleoside therapy Ziagen + Combivir with protease inhibitor plus Combivir regimens in therapy-nave
7. Two studies compare triple nucleoside therapy Ziagen® + Combivir® with protease inhibitorplus Combivir® regimens in therapy-naive patients
8. COX-2 inhibitors associated with blood pressure elevation
9. COX-2 inhibitor increases the risk of heart attack in elderly adults with no history of heart attack
10. More studies on risks and benefits of COX-2 inhibitors published in Archives of Internal Medicine
11. Penn researchers add more evidence to demonstrate role of COX inhibitors in heart-disease risk

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/17/2019)... ... July 17, 2019 , ... Becker's Healthcare is pleased ... , The men and women included on this list lead organizations regularly recognized ... implementations as well as the construction of satellite clinics and strategic partnerships with ...
(Date:7/17/2019)... ... July 17, 2019 , ... ... client engagement options for human services providers worldwide, has been awarded a California ... program streamlines the procurement process for state and local government agencies in California ...
(Date:7/17/2019)... ... ... A new study led by researchers at the University of Pittsburgh and ... for the first time that New York’s sepsis protocols are directly responsible for the ... to infection. It kills more than 275,000 Americans each year and leaves hundreds of ...
(Date:7/17/2019)... ... 2019 , ... Women’s Excellence is pleased to announce a new office opening in Lapeer, Michigan. ... offices resides on the corner of Turrill Road and South Lapeer Roads, conveniently off of ... opening of our new office in Lapeer and the ability to service women in this ...
(Date:7/13/2019)... ... ... ZALO , the leading luxury sex toy manufacturer, is now shipping ... view the product and its accompanying video click here . , “We are ... around the world,” said Mara Epstein, director of sales. “The Hero provides a unique ...
Breaking Medicine News(10 mins):
(Date:7/18/2019)... CHARLOTTE, N.C. (PRWEB) , ... July 18, 2019 ... ... management, and exclusion screening solutions for over 20 years, announced today it is ... for its premier services. , “We are thrilled to be moving into ...
(Date:7/17/2019)... , ... July 17, 2019 , ... Princeton, New Jersey ... services, today announced that it has been named a 2019 ‘Cool Vendor’ by Gartner, ... for this year’s Cool Vendors research, we focused on two things. First, given the ...
(Date:7/17/2019)... , ... July 17, 2019 , ... Highmark Health, Allegheny ... soccer enthusiasts from around the region to announce plans for what will be one ... Located in Coraopolis on State Avenue and adjacent to the Montour Trail, the complex ...
Breaking Medicine Technology:
Cached News: